DLBCL
Pola-R-CHP may be cost-effective for the treatment of DLBCL.
A new model that makes use of a promising imaging biomarker can predict diffuse large B-cell lymphoma relapse and survival ...
The U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to nanatinostat and valganciclovir for the ...
Advertisement
Research indicates that Hispanic patients with DLBCL have better survival than non-Hispanic White.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.